Vir Biotechnology Inc. (VIR) and GlaxoSmithKline's (GSK) Sotrovimab Retains Activity Against Key Omicron Mutations, per Preclinical Data

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. GOOGL
6. ABBV
7. DFTX
8. USO
9. APGE
10. HOOD

Go back to Vir Biotechnology Inc. (VIR) and GlaxoSmithKline's (GSK) Sotrovimab Retains Activity Against Key Omicron Mutations, per Preclinical Data

Preclinical Data Demonstrate Sotrovimab Retains Activity Against Key Omicron Mutations, New SARS-CoV-2 Variant

December 2, 2021 2:08 AM EST

  Preclinical data demonstrate sotrovimab, authorized in multiple countries around the world, retains activity against all tested variants of concern, including key mutations of Omicron

Data to be confirmed by further in vitro pseudo-virus testing

LONDON and SAN FRANCISCO, Dec. 02, 2021 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced an update to... More